Amino acid derivatives as calcium channel blockers
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or an aromatic or heteroaromatic ring.
1 . A method to treat a condition modulated by calcium ion channel activity, which method comprises administering to a subject in need of such treatment an amount of the compound of formula (1) effective to ameliorate said condition, wherein said compound is of the formula:
or a pharmaceutically acceptable salt or conjugate thereof, wherein
X is an optionally substituted benzhydryl, aryl (6-10C) or heteroaryl (5-12C);
Ar is an optionally substituted aryl (6-10C) or heteroaryl (5-12C);
R 1 and R 3 are independently H or methyl;
R 2 is H, or an optionally substituted alkyl (1-3C), alkenyl (2-3C), alkynyl (2-3C), heteroalkyl (2-3C), heteroalkenyl (2-3C), heteroalkynyl (2-3C),
or R 1 and R 2 may together form an optionally substituted heterocyclic ring having 3 to 8 member atoms;
wherein the optional substituents on each Ar, X and R 2 are independently selected from halo, CN, NO 2 , CF 3 , OCF 3 , COOR′, CONR′ 2 , OR′, SR′, SOR′, SO 2 R′, NR′ 2 , NR′(CO)R′, NR′SO 2 R′, —Si(CH 3 ) 3 , —CH 2 CN, —C(CH 3 ) 2 CN, —C(CH 3 ) 2 CH 2 OR′, —C(CH 3 ) 2 CO 2 R′, —C(CH 3 ) 2 CONHR′ and —C(CH 3 ) 2 CONR′ 2 wherein each R′ is independently H or an optionally substituted group selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C); or the optional substituents may be one or more optionally substituted groups selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C) and phenyl; and wherein the optional substituent on R 2 may further be selected from ═O and ═NOR′
with the proviso that R 2 is not CH 2 COOH if X is an unsubstituted phenyl.
2 . The method of claim 1 wherein said condition is modulated by N-type or T-type or both N-type and T-type calcium channel activity.
3 . The method of claim 1 wherein said condition is chronic or acute pain, mood disorders, neurodegenerative disorders, gastrointestinal disorders, genitourinary disorders, neuroprotection, metabolic disorders, cardiovascular disease, epilepsy, diabetes, cancer, sleep disorders, Parkinson's disease, schizophrenia or male birth control.
4 . The method of claim 1 wherein said condition is chronic or acute pain.
5 . The method of claim 1 wherein X is an optionally substituted benzhydryl.
6 . The method of claim 1 wherein X is an optionally substituted phenyl.
7 . The method of claim 1 wherein Ar is an optionally substituted phenyl, pyridinyl, or naphthyl.
8 . The method of claim 1 wherein both R 1 are H.
9 . The method of claim 1 wherein R 2 is H or methyl.
10 . The method of claim 1 wherein Ar is:
wherein each R″ and Y are independently H, halo, CN, NO 2 , CF 3 , OCF 3 , COOR′, CONR′ 2 , OR′, SR′, SOR′, SO 2 R′, NR′ 2 , NR′(CO)R′, NR′SO 2 R′, —Si(CH 3 ) 3 , —CH 2 CN, —C(CH 3 ) 2 CN, —C(CH 3 ) 2 CH 2 OR′, —C(CH 3 ) 2 CO 2 R′, —C(CH 3 ) 2 CONHR′ and —C(CH 3 ) 2 CONR′ 2 wherein each R′ is independently H or an optionally substituted group selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C); or the optional substituents may be one or more optionally substituted groups selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C).
11 . The method of claim 10 wherein both R″ are the same.
12 . The method of claim 10 wherein each R″ is independently H, halo, CH(CH 3 ) 2 , cyclopropyl, C(CH 3 ) 3 , CH 3 , CF 3 , Si(CH 3 ) 3 , CH 2 CN, C(CH 3 ) 2 CN, C(CH 3 ) 2 CH 2 OR′, C(CH 3 ) 2 CO 2 R′, C(CH 3 ) 2 CONHR′, or C(CH 3 ) 2 CONR′ 2 .
13 . The method of claim 12 wherein each R″ is independently H, halo, CH(CH 3 ) 2 , cyclopropyl, C(CH 3 ) 3 , CH 3 , or CF 3 ,
14 . The method of claim 10 wherein Y is H, halo, alkyl (1-6C) or OR′ wherein R′ is an alkyl(1-6C).
15 . A pharmaceutical composition comprising a compound of the formula:
or a pharmaceutically acceptable salt or conjugate thereof, wherein
X is an optionally substituted benzhydryl, aryl (6-10C) or heteroaryl (5-12C);
Ar is an optionally substituted aryl (6-10C) or heteroaryl (5-12C);
R 1 and R 3 are independently H or methyl;
R 2 is H, or an optionally substituted alkyl (1-3C), alkenyl (2-3C), alkynyl (2-3C), heteroalkyl (2-3C), heteroalkenyl (2-3C), heteroalkynyl (2-3C),
or R 1 and R 2 may together form an optionally substituted heterocyclic ring having 3 to 8 member atoms;
wherein the optional substituents on each Ar, X and R 2 are independently selected from halo, CN, NO 2 , CF 3 , OCF 3 , COOR′, CONR′ 2 , OR′, SR′, SOR′, SO 2 R′, NR′ 2 , NR′(CO)R′, NR′SO 2 R′, —Si(CH 3 ) 3 , —CH 2 CN, —C(CH 3 ) 2 CN, —C(CH 3 ) 2 CH 2 OR′, —C(CH 3 ) 2 CO 2 R′, —C(CH 3 ) 2 CONHR′ and —C(CH 3 ) 2 CONR′ 2 wherein each R′ is independently H or an optionally substituted group selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C); or the optional substituents may be one or more optionally substituted groups selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C) and phenyl; and wherein the optional substituent on R 2 may further be selected from ═O and ═NOR′
with the proviso that R 2 is not CH 2 COOH if X is an unsubstituted phenyl.
16 . The pharmaceutical composition of claim 16 wherein X is an optionally substituted benzhydryl.
17 . The pharmaceutical composition of claim 16 wherein X is an optionally substituted phenyl.
18 . The pharmaceutical composition of claim 16 wherein Ar is an optionally substituted phenyl, pyridinyl, or naphthyl.
19 . The pharmaceutical composition of claim 16 wherein both R 1 are H.
20 . The pharmaceutical composition of claim 16 wherein R 2 is H or methyl.
21 . The pharmaceutical composition of claim 16 wherein Ar is:
wherein each R″ and Y are independently H, halo, CN, NO 2 , CF 3 , OCF 3 , COOR′, CONR′ 2 , OR′, SR′, SOR′, SO 2 R′, NR′ 2 , NR′(CO)R′, NR′SO 2 R′, —Si(CH 3 ) 3 , —CH 2 CN, —C(CH 3 ) 2 CN, —C(CH 3 ) 2 CH 2 OR′, —C(CH 3 ) 2 CO 2 R′, —C(CH 3 ) 2 CONHR′ and —C(CH 3 ) 2 CONR′ 2 wherein each R′ is independently H or an optionally substituted group selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C); or the optional substituents may be one or more optionally substituted groups selected from alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), heteroalkyl (2-6C), heteroalkenyl (2-6C), heteroalkynyl (2-6C).
22 . The pharmaceutical composition of claim 22 wherein both R″ are the same.
23 . The pharmaceutical composition of claim 22 wherein each R″ is independently H, halo, CH(CH 3 ) 2 , cyclopropyl, C(CH 3 ) 3 , CH 3 , CF 3 , Si(CH 3 ) 3 , CH 2 CN, C(CH 3 ) 2 CN, C(CH 3 ) 2 CH 2 OR′, C(CH 3 ) 2 CO 2 R′, C(CH 3 ) 2 CONHR′, or C(CH 3 ) 2 CONR′ 2 .
24 . The pharmaceutical composition of claim 22 wherein each R″ is independently H, halo, CH(CH 3 ) 2 , cyclopropyl, C(CH 3 ) 3 , CH 3 , or CF 3 ,
25 . The pharmaceutical composition of claim 22 wherein Y is H, halo, alkyl (1-6C) or OR′ wherein R′ is an alkyl(1-6C).